Search

Displaying results 3311 - 3320 of 7540 in total
  1. Drug

    Encainide

    go.drugbank.com/drugs/DB01228
    ApprovedWithdrawn

    The manufacturer of Enkaid capsules voluntarily withdrew the product from the US market on December 16, 1991.

    Synonyms: (±)-4-methoxy-N-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)benzamide, 4-Methoxy-N-{2-[2-(1-methyl-piperidin-2-yl)-ethyl]-phenyl}-benzamide
  2. Drug

    Zilpaterol

    go.drugbank.com/drugs/DB11479
    ExperimentalVet approved

    Zilpaterol is a β2 adrenergic agonist sold under the trade name, Zilmax, produced by Intervet, a subsidiary of Merck & Co. … Zilpaterol is typically fed to cattle in the last three to six weeks of life with a brief washout period to clear the drug from the tissues before slaughter.

  3. Drug

    INO-4800

    go.drugbank.com/drugs/DB15693
    Investigational

    [A214475] Early _in vitro_ studies using HEK-293T cells demonstrated that the transfection of INO-4800 results in the expression of S protein by human cells. … [A214475] A Phase 1 clinical trial for INO-4800 in the U.S. (NCT04336410) was started on April 3, 2020, with an expected completion date of July 2021.

    Synonyms: INO-4800 DNA Coronavirus Vaccine
  4. Drug

    Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen

    go.drugbank.com/drugs/DB10284
    ApprovedInvestigational

    by *Neisseria meningitidis* serogroup B. … It is contained in the suspension of Trumenba, which is a vaccine is composed of two recombinant lipidated factor H binding protein (fHBP) variants from N. meningitidis serogroup B, one from fHBP subfamily

  5. Drug

    Stannsoporfin

    go.drugbank.com/drugs/DB04912
    Investigational

    Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing

  6. Drug

    OSI-7836

    go.drugbank.com/drugs/DB05837
    Experimental

    This drug shows no unexpected toxicities; those observed appeared to be similar to other nucleoside agents. … The anti-tumor activity of OSI-7836 appeares to be less schedule dependent than gemcitabine.

  7. Drug

    Regorafenib

    go.drugbank.com/drugs/DB08896
    ApprovedInvestigational

    FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.

  8. Drug

    Cobalamin

    go.drugbank.com/drugs/DB14098
    ApprovedInvestigational

    Mixtures: Folika-NC
  9. Drug

    Quinfamide

    go.drugbank.com/drugs/DB12780
    Investigational

    Quinfamide has been used in trials studying the treatment of Amoebiasis and Helminthiasis.

    Mixtures: LOXCELL NF, LO-BRUQUIN
  10. Drug

    Pomaglumetad methionil

    go.drugbank.com/drugs/DB05096
    Investigational

    For LY2140023, the active substance, LY404039, is thought to work by reducing the presynaptic release of another neurotransmitter, glutamate, in brain regions where mGlu2/3 receptors are expressed. … Most currently approved antipsychotic medications work by affecting the neurotransmitters dopamine or serotonin.